ASP Isotopes outlines commercialization milestones and $300M EBITDA target

ASP Isotopes said at its inaugural Capital Markets Day in London that it is transitioning from development into early commercialization, with milestones intended to drive revenues and a $300 million EBITDA target for 2031.